Objectives: Mecillinam is recommended in France as a first-line treatment for lower urinary tract infections, due to the large increase in resistance of Escherichia coli to other oral treatments, such as co-trimoxazole or fluoroquinolones, its limited impact on faecal microbiota and its stability in the presence of numerous b-lactamases. However, we recently identified several mecillinam-resistant E. coli isolates with a high-level expression penicillinase (HEP) phenotype that merit further study.
Introduction
Mecillinam (amdinocillin) is an extended-spectrum penicillin antibiotic with a high affinity for Escherichia coli PBP-2. Mecillinam resistance in E. coli is low in Europe, ranging from 0.5% to 6.5%. 1, 2 Mecillinam is recommended in France as a first-line treatment for uncomplicated lower urinary tract infections, because of the large increase in resistance of E. coli to oral treatment, including co-trimoxazole or fluoroquinolones, and its limited impact on faecal microbiota. 1, 3, 4 Several mechanisms of mecillinam resistance have been described, such as mutations in metabolic genes or the production of certain b-lactamases. 5 However, mecillinam is more stable than other b-lactams in the presence of b-lactamases, [5] [6] [7] highlighted by the low resistance rate among ESBL-producing Enterobacteriaceae (from 2.1% to 10%). 6, 8 Nonetheless, several mecillinam-resistant E. coli isolates have been identified that do not produce OXA b-lactamase or ESBL but have a high-level expression penicillinase (HEP) phenotype. 9, 10 In this study, we show that the presence of an SNP in the promoter of the plasmidic TEM-1 b-lactamase gene can confer resistance to mecillinam by comparing two isogenic isolates, one resistant to mecillinam and one susceptible to mecillinam. This resistance was abolished by the synergistic activity of the combination of mecillinam and amoxicillin/clavulanate, measured by a simple test to determine the MIC of this combination, suitable for daily laboratory practice. 
Materials and methods

Bacterial isolates and antibiotic susceptibility
We retrospectively determined the mecillinam resistance rate of E. coli isolated from clinical samples of paediatric patients or their mothers (urines, blood samples or vaginal samples) based on microbiological data collected in the laboratory from 1 November 2015 to 31 March 2016. During this period, the susceptibility of 880 clinical E. coli isolates to b-lactams was studied. Antibiotic susceptibility was determined using the disc diffusion method on Mueller-Hinton agar and interpreted as specified by EUCAST. Isolates resistant to amoxicillin, amoxicillin/clavulanate and piperacillin/ tazobactam, but susceptible to third-generation cephalosporins (ceftriaxone, cefotaxime, ceftazidime) and a cephamycin (cefoxitin), were considered to have an HEP phenotype.
9,10 ESBL production was defined as synergy between clavulanate and at least one extended-spectrum cephalosporin (ceftazidime, cefotaxime or cefepime) or aztreonam. Two E. coli isolates from the same patient were used for nextgeneration sequencing: one that was mecillinam resistant, obtained from a blood sample (40083-R), and one that was mecillinam susceptible, cultured from his urine (40089-S).
MICs of mecillinam, amoxicillin and amoxicillin/clavulanate were determined by the Etest method (Oxoid, Dardilly, France, and AB bioMérieux, Solna, Sweden, respectively) on Mueller-Hinton agar with a standard inoculum (10 6 cfu/mL) and a high inoculum (10 8 cfu/mL). The Etest was also used to evaluate the activity of mecillinam ! amoxicillin and mecillinam ! amoxicillin/clavulanate. The principle of this test has been described previously.
11 Briefly, one amoxicillin or amoxicillin/clavulanate strip is placed on a Mueller-Hinton agar plate for 30 min then removed, and a mecillinam strip is placed on top of the gradient of the first agent. The MIC of the combination was interpreted as the value at which the inhibition zone intersected the scale on the mecillinam Etest strip.
Genetic analysis PCR assays
bla TEM and its promoter were amplified and sequenced as described previously.
12
Plasmid extraction and electroporation
Plasmids of 40083-R and 40089-S were extracted using the PureYield TM Plasmid Miniprep System (Promega, Charbonnières-les-bains, France) and electroporated into E. coli DH5a (Invitrogen). Selection was performed on LB medium containing 100 mg/L amoxicillin.
WGS
The whole genomes of isolates 40083-R and 40089-S were sequenced using the Nextera kit (Illumina) to prepare the library. The sequencing was performed using a MiSeq reagent kit V3 600 cycles (Illumina Technology). Sequences were analysed using the Center for Genomic Epidemiology website (http://www.genomicepidemiology.org). Genes were annotated using Rast software (version 2.0), and the sequences were aligned and compared using BioEdit Sequence Alignment Editor (version 7.2.5).
Results
Among the 880 E. coli isolates collected in the laboratory between November 2015 and March 2016, the overall rate of mecillinam resistance was 4.8% (n " 42). Among these, 78.5% (33/42) had an HEP phenotype, 16.7% (7/42) had an ESBL phenotype and 4.8% (2/42) harboured another resistance mechanism.
The strain causing bacteraemia (40083-R) was resistant to amoxicillin, amoxicillin/clavulanate, piperacillin/tazobactam, mecillinam, co-trimoxazole, minocycline and nalidixic acid. The resistance phenotype to b-lactams suggested an HEP phenotype. 9, 10 The strain isolated from the urine of the same patient (40089-S) had the same resistance phenotype, but was susceptible to amoxicillin/clavulanate, piperacillin/tazobactam and mecillinam, suggesting low-level expression of penicillinase. The observed resistance of both strains was transferable to E. coli DH5a, suggesting that it was plasmid mediated.
For WGS, a total of 727 contigs (from 0.3 to 100 kb) and 681 contigs (from 0.3 to 123 kb) were obtained for 40083-R and 40089-S, respectively.
Global comparison revealed that the two isolates are genetically related, with .99.5% similarity, and belong to ST10 and to the O86:H2 serotype. The resistance genes confirmed the observed resistance phenotype {bla TEM-1B , sul2, dfrA8, qnrB19, strB [aph(6)-Id], strA [aph(3 00 )-Ib] and tet(B)}. The only b-lactamase gene found in both isolates was bla TEM-1B . We compared the DNA of the two isolates containing the TEM-1B b-lactamase gene, in particular the promoter sequences, to investigate their different resistance to blactams. The only difference identified was the mutation C32T according to the Sutcliffe numbering system in the TEM-1B promoter of 40083-R. This mutation corresponds to the Pa/Pb promoter, known to increase the expression of the penicillinase relative to the regular promoter P3. 13 We found no other differences between the two isolates in genes reported to confer mecillinam resistance.
14 Susceptibility of 40083-R to mecillinam was restored when mecillinam was combined with amoxicillin/clavulanate, even at a high inoculum. No synergy was observed between mecillinam and amoxicillin, suggesting that the synergy is due to clavulanate (Table 1) . Transconjugants gave the same results. Overall, these results suggest that the HEP phenotype is due to the high production of TEM-1, resulting from a point mutation in the b-lactamase promoter, and that amoxicillin/clavulanate can efficiently restore mecillinam activity. We examined the generalization of this observation by determining the MICs of mecillinam, amoxicillin, amoxicillin/clavulanate, mecillinam ! amoxicillin and mecillinam ! amoxicillin/clavulanate at a normal inoculum (10 6 cfu/mL) and a high inoculum (10 8 cfu/mL) for 9 unrelated strains representative of the 33 mecillinam-resistant isolates of our collection with an HEP phenotype. Of these, 6/9 harboured the same single mutation in the promoter (Pa/Pb promoter) and the remaining three had a P3 promoter. The inhibition zone around mecillinam (10 lg) for all isolates was ,15 mm, categorizing them as resistant according to EUCAST breakpoints. However, the mecillinam MICs were variable, ranging from 2 to 4 mg/L at a normal inoculum, thus susceptible (susceptible if MIC ,8 mg/L), but with a higher MIC than for WT strains (modal MIC is 0.125 mg/L; EUCAST). At a high inoculum, the nine isolates were resistant, with MICs .256 mg/L. Mecillinam ! amoxicillin/clavulanate decreased the MIC of mecillinam to 1 mg/L for all strains for both inocula. No variations in mecillinam MICs were observed when combined with amoxicillin, showing the absence of synergy between the two b-lactams (Table 1) .
Our study shows that amoxicillin/clavulanate can protect the activity of mecillinam in vitro. This association is independent of the inoculum and the in vitro Etest can easily detect the synergy of Birgy et al.
these agents, which is practical for routine use in clinical laboratories.
Discussion
Resistance to mecillinam is generally low among E. coli isolates. 15 Among the 880 E. coli isolates studied in our laboratory, 4.8% (n " 42) were mecillinam resistant and 78.5% (n " 33) of the resistant isolates expressed an HEP phenotype, although this molecule is resistant to hydrolysis by most b-lactamases. [5] [6] [7] 16 TEM-1 is disseminated worldwide and almost 50% of E. coli isolates harbour this b-lactamase. A single mutation in the P3 promoter can transform it into a Pa/Pb promoter, conferring high-level expression of TEM penicillinase. 13 Here, using two natural isogenic plasmids, we showed that high penicillinase expression (induced by the Pa/Pb promoter) can confer mecillinam resistance in vitro. This mutation is not the only mechanism able to confer an HEP phenotype, but was the most frequently observed in our mecillinamresistant clinical isolates.
The combination of mecillinam and b-lactamase inhibitors synergistically and efficiently reduces the mecillinam MIC for ESBL producers in vitro. 8 This combination could be an efficient treatment for lower urinary tract infections caused by ESBL-producing E. coli. 2, 8 To our knowledge, no medicines with clavulanate alone are commercially available requiring the use of mecillinam ! amoxicillin/clavulanate. It could be effective against most inhibitor-sensitive b-lactamase-producing E. coli at any inoculum, as it reduced the MIC for our mecillinam-resistant isolates to a level compatible with therapeutic use. We demonstrated a practical test to determine the MIC of mecillinam ! amoxicillin/clavulanate for routine use in clinical laboratories. A simple approach would be to determine the MIC of the combination before treating patients.
Mecillinam has proven its clinical efficacy and safety for empirical treatment of uncomplicated urinary tract infections, resulting in clinical and bacteriological cure rates similar to those obtained with other urinary tract infection agents. It can be taken by pregnant women and children old enough to swallow tablets. 3, 17 Mecillinam has a very small impact on the normal oropharyngeal, intestinal and skin microflora, thus limiting selection for resistance. 4 This is in contrast with other b-lactams, in particular cefixime, an oral cephalosporin that selects ESBL-producing Enterobacteriaceae. 18 Studies have suggested the possible use of mecillinam as a relay for the treatment of uncomplicated acute pyelonephritis, showing an efficient bacterial and clinical cure rate. [19] [20] [21] In Denmark (http://pro.medicin.dk/Specielleemner/Emner/318561 #a000) and Norway (www.helsebiblioteket.no), mecillinam, taken orally at a dose of 400 mg three times daily, for 7-14 days, is also recommended for the treatment of acute pyelonephritis without signs of urosepsis. The plasma half-life of mecillinam is 1 h and the peak serum concentration is only modest (4-5 mg/L) for a single oral administration of 400 mg. However, the post-antibiotic effect is long for a b-lactam: 3 h for a peak serum concentration of 1 mg/L and 4.6 h when combined with ampicillin at the same peak serum concentration. 22 Furthermore, binding to plasma protein is only 10%-15%. Here, we show that mecillinam! amoxicillin/ clavulanate is not sensitive to the inoculum effect for isolates with an HEP phenotype. The combination of mecillinam and amoxicillin/clavulanate could be an alternative as a relay for the treatment of non-complicated acute pyelonephritis when no other oral Resistance of high-level TEM-1-producing E. coli to mecillinam JAC treatment is possible, although further clinical evaluation for this indication is needed.
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